Last reviewed · How we verify
Methotrexate - Delay
Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, disrupting DNA synthesis and cell division.
Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, disrupting DNA synthesis and cell division. Used for Treatment of certain types of cancer, including leukemia and lymphoma, and autoimmune diseases like rheumatoid arthritis and psoriasis, Prevention of organ transplant rejection.
At a glance
| Generic name | Methotrexate - Delay |
|---|---|
| Also known as | Experimental methotrexate treatment |
| Sponsor | University Hospital, Montpellier |
| Drug class | Antimetabolite |
| Target | Dihydrofolate reductase |
| Modality | Small molecule |
| Therapeutic area | Oncology, Immunology, Rheumatology |
| Phase | Phase 3 |
Mechanism of action
This action leads to the inhibition of rapidly dividing cells, such as cancer cells and certain immune cells. Methotrexate also has anti-inflammatory properties, which contribute to its therapeutic effects in conditions like rheumatoid arthritis.
Approved indications
- Treatment of certain types of cancer, including leukemia and lymphoma, and autoimmune diseases like rheumatoid arthritis and psoriasis
- Prevention of organ transplant rejection
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Fatigue
- Hair loss
- Liver enzyme elevation
- Bone marrow suppression
- Pancytopenia
- Alopecia
- Neutropenia
Key clinical trials
- Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) (PHASE3)
- Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (PHASE2)
- Treatment for Ph-negative ALL for Adults up to 65 Years (NA)
- Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia (PHASE3)
- Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms (PHASE2)
- Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma (PHASE2)
- Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia (PHASE1)
- Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methotrexate - Delay CI brief — competitive landscape report
- Methotrexate - Delay updates RSS · CI watch RSS
- University Hospital, Montpellier portfolio CI